Department of Endocrinology, Metabolism and Prevention of Cardiovascular DiseasesThe Endocrinology-Metabolism department headed by Prof. Bruckert comprises two units: one for hypothalamic-pituitary pathologies and a unit for the management of severe dyslipidemia (Lipidology).The lipidology unit includes
- a day hospital platform (55 patients per week) and functional exploration for cardiovascular prevention (stress test, echocardiography, evaluation of retinal microcirculation by optical coherence, Echo-Doppler of peripheral arteries
- A functional LDL apheresis treatment unit (80 patients) within a common hemobiotherapy federation,
- A consultation platform (7000 consultations for dyslipidemia per year).
Areas of clinical and research expertise
- the management of lipid diseases (excess triglyceride cholesterol, metabolic syndrome) with international notoriety on the rarest and most serious diseases (for example 50 homozygous familial hypercholesterolaemia, 4 patients with Refsum disease, 30 familial hyperchylomicronemia, 8 patients with sistosterolemia, 5000 patients with heterozygous familial hypercholesterolemia including more than 400 children)
- The pathologies treated in the department require therapeutic education programs, in particular for the metabolic syndrome. These are validated by the ARS
- The unit benefits from an exceptional environment with up-to-date radiology services (coroscanner, calcium score), genetics (genetic diagnosis of familial hypercholesterolemia, hyperchylomicronemia and genetic hypoHDLemia) and lipidology (hormonal assays and assays of lipids including the most specialized assays)
- The unit coordinates with the Marseille center the national register of familial hypercholesterolemia.
Recent major publications02/01/2020A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke08/07/2021The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia13/04/2021Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force27/08/2020Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment28/03/2020PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS studyMembers of the teamEric BruckertPU-PH, head of departmentXavier GirardPU-PHPhilippe GiralMCU-PHAntonio GalloFull time doctorFind out more
